Medtech company RSP Systems completed its third series B financing round, ensuring the firm a total amount of EUR 13.1 million (USD 14.96 million). The funding is to facilitateEuropean launch of a non-invasive glucose monitoring device. At the same time, the company says goodbye to five in eight board members.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.